Background: Second primary colorectal adenocarcinomas (SPCA) may occur with a higher frequency in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). In a nationwide population-based study, we investigated the risk of SPCA in GEP-NEN patients and compared it to the general population. Methods: Using the nationwide Danish registries, we identified 2,831 GEP-NEN patients (median age 63 years [IQR 50–73 years], 53% women) diagnosed in 1995–2010. We used Cox regression to compare the incidence of SPCA in GEP-NEN patients relative to a gender- and age-matched general population sample of 56,044 persons. Results: We observed 20 SPCAs among the 2,831 GEP-NEN patients with a total time at risk of 14,003 years (incidence = 143 per 100,000 person-years) and 770 colorectal adenocarcinomas in the general population of 56,044 persons with a total time at risk of 466,801 years (incidence = 165 per 100,000 person-years). The hazard ratio (HR) of SPCA from GEP-NEN diagnosis to the end of follow-up was 1.22 (95% CI: 0.78–1.92) in GEP-NEN patients compared to the general population. This nonsignificant association was the result of a strong positive association in the first 6 months after diagnosis of GEP-NEN (HR = 9.43 [95% CI: 4.98–17.86]) followed by a negative association in the remainder of the follow-up period (HR = 0.50 [95% CI: 0.20–1.21]). Conclusion: In this population-based study, there was no increased risk of SPCA among GEP-NEN patients. The clinical workup in newly diagnosed GEP-NEN patients likely explains the positive short-term association followed by a negative association.

Keywords:
Neuroendocrine neoplasms, Second primary malignancies, Second primary colorectal adenocarcinomas, Clinical epidemiology
1.
Öberg K, Knigge U, Kwekkeboom D, Perren A; ESMO Guidelines Working Group: Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl 7):vii124–130.
2.
Gerstle JT, Kauffman GL, Jr., Koltun WA: The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies. J Am Coll Surg 1995; 180: 427–432.
3.
Lindor NM, Greene MH: The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90: 1039–1071.
4.
Zucker KA, Longo WE, Modlin IM, Bilchik AJ, Adrian TE: Malignant diathesis from jejunal-ileal carcinoids. Am J Gastroenterol 1989; 84: 182–186.
5.
Rehfeld JF: The new biology of gastrointestinal hormones. Physiol Rev 1998; 78: 1087–1108.
6.
Habal N, Sims C, Bilchik AJ: Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 2000; 75: 310–316.
7.
Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444–448.
8.
Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS: Second cancers in patients with neuroendocrine tumors. PLoS One 2013; 8:e86414.
9.
Westergaard T, Frisch M, Melbye M: Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. Cancer 1995; 76: 106–109.
10.
Kamp K, Damhuis RA, Feelders RA, de Herder WW: Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocr Relat Cancer 2012; 19: 95–99.
11.
Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L: Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2010; 2: 51–56.
12.
Gjerstorff ML: The Danish Cancer Registry. Scand J Public Health 2011; 39: 42–45.
13.
Jepsen P, Vilstrup H, Andersen PK: The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. Hepatology 2015; 62: 292–302.
14.
Kothari T, Mangla JC: Malignant tumors associated with carcinoid tumors of the gastrointestinal tract. J Clin Gastroenterol 1981; 3(suppl 1): 43–46.
15.
Tichansky DS, Cagir B, Borrazzo E, Topham A, Palazzo J, Weaver EJ, Lange A, Fry RD: Risk of second cancers in patients with colorectal carcinoids. Dis Colon Rectum 2002; 45: 91–97.
16.
Amin S, Warner RR, Itzkowitz SH, Kim MK: The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study. Endocr Relat Cancer 2012; 19: 381–387.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.